Acute promyelocytic leukemia: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Brian Blank (talk | contribs)
nocaptcha
2,344 edits
No edit summary
 
Sogand (talk | contribs)
4,941 edits
No edit summary
 
(18 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
   Name          = Acute promyelocytic leukemia |
   Name          = Acute promyelocytic leukemia |
Line 12: Line 13:
   DiseasesDB    = |
   DiseasesDB    = |
}}
}}
{{SI}}
{{Acute promyelocytic leukemia}}
{{CMG}}
'''For patient information click [[Leukemia (patient information)|here]]'''


{{Editor Help}}
{{CMG}}; {{AE}} {{S.G.}} {{GRR}} {{Nat}}


==Overview==
{{SK}} Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant
'''Acute promyelocytic leukemia''' is a subtype of [[acute myelogenous leukemia]] (AML), a [[cancer]] of the [[blood]] and [[bone marrow]]. It is also known as '''acute progranulocytic leukemia'''; '''APL'''; '''AML with t(15;17)(q22;q12)''', '''PML-RARA and variants'''; '''FAB subtype M3 and M3 variant'''.


In APL, there is an abnormal accumulation of immature [[granulocytes]] called promyelocytes.  The disease is characterized by a [[chromosomal translocation]] involving the [[retinoic acid receptor]] alpha (''RARα'' or ''RARA'') gene and is unique from other forms of AML in its responsiveness to [[ATRA|all ''trans'' retinoic acid]] (ATRA) therapy.
==[[Acute promyelocytic leukemia overview|Overview]]==


==Signs and symptoms==
==[[Acute promyelocytic leukemia historical perspective|Historical Perspective]]== 
Signs and symptoms of acute promyelocytic leukemia are similar to other forms of AML.  Symptoms include [[fever]], [[fatigue (physical)|fatigue]], [[weight loss]] or loss of appetite, shortness of breath with exertion, [[anemia]], easy bruising or bleeding, [[petechiae]] (flat, pin-head sized spots under the skin caused by bleeding), bone pain and joint pain and persistent or frequent infections.[8]


The accumulation of promyelocytes in the bone marrow results in a reduction in the production of normal [[red blood cell]]s and [[platelet]]s resulting in [[anemia]] and [[thrombocytopenia]].  Either [[leukopenia]] (low white cell count) or [[leukocytosis]] (high white cell count) may be observed in the peripheral blood. 
==[[Acute promyelocytic leukemia classification|Classification]]==
Symptoms include:
*Fatigue, weakness, shortness of breath (from anemia)
*Easy bruising and bleeding (from thrombocytopenia and [[coagulopathy]])
*Fever and infection (from lack of normal white blood cells)


In addition, acute promyelocytic leukemia is frequently associated with bleeding caused by [[disseminated intravascular coagulation]] (DIC).
==[[Acute promyelocytic leukemia pathophysiology|Pathophysiology]]==


==Epidemiology==
==[[Acute promyelocytic leukemia differential diagnosis|Differentiating Acute promyelocytic leukemia from Other Diseases]]==
Acute promyelocytic leukemia represents 5-8% of AML in adults. The median age is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years).  The incidence is increased in patients originated in Latin American countries.(Douer ''et al.'')


==Pathogenesis==
==[[Acute promyelocytic leukemia epidemiology and demographics|Epidemiology and Demographics]]==
Acute promyelocytic leukemia is characterized by chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (''RARα'').  In 95% of cases of APL, retinoic acid receptor-alpha (''RARα'') gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (''PML'') on chromosome 15, a translocation denoted as t(15;17)(q22;q12).


Four other gene rearrangements have been described in APL fusing ''RARα'' to promyelocytic leukemia zinc finger (''PLZF''), nucleophosmin (''NPM''), nuclear matrix associated (''NUMA''), or signal transducer and activator of transcription  5b (''STAT5B'') genes.
==[[Acute promyelocytic leukemia risk factors|Risk Factors]]==


The resultant fusion proteins disrupt the function of RARα which blocks the normal maturation of granulocytes.  Although the chromosomal translocation involving ''RARα'' is believed to be the initiating event, additional mutations are required for the development of leukemia.
==[[Acute promyelocytic leukemia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==


==Diagnosis==
==Diagnosis==
Acute promyelocytic leukemia can be distinguished from other types of AML based on morphologic examination of a [[bone marrow biopsy]] or aspirate.  Definitive diagnosis requires testing for the ''RARα'' fusion gene. This may be done by [[polymerase chain reaction]] (PCR), [[fluorescent in situ hybridization]] (FISH), or conventional [[cytogenetics]] of peripheral blood or bone marrow.
[[Acute promyelocytic leukemia history and symptoms|History and Symptoms]] | [[Acute promyelocytic leukemia physical examination|Physical Examination]] | [[Acute promyelocytic leukemia laboratory findings|Laboratory Findings]] | [[Acute promyelocytic leukemia other imaging studies|Other Imaging studies]] | [[Acute promyelocytic leukemia other diagnostic studies|Other Diagnostic Studies]]
 
Monitoring for relapse using PCR tests for ''RARα'' allows early re-treatment which is successful in many instances.


==Treatment==
==Treatment==
APL is unique among the leukemias distinguished by its sensitivity to [[all-trans retinoic acid|all-''trans'' retinoic acid]] (ATRA), a derivative of [[vitamin A]].  Treatment with ATRA causes differentiation of the immature leukemic promyelocytes into mature granulocytes.  ATRA is typically combined with [[anthracycline]] based chemotherapy resulting in a clinical remission in approximately 90% of patients. 
[[Acute promyelocytic leukemia medical therapy|Medical Therapy]] | [[Acute promyelocytic leukemia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Acute promyelocytic leukemia future or investigational therapies|Future or Investigational Therapies]]


ATRA therapy is associated with the unique side effect of [[retinoic acid syndrome]].  This is associated with the development of dyspnea, fever, weight gain, peripheral edema and is treated with [[dexamethasone]].  The etiology of retinoic acid syndrome has been attributed to capillary leak syndrome from cytokine release from the differentiating promyelocytes. 
==Case Studies==
[[Acute promyelocytic leukemia case study one|Case #1]]


Treatment options for patients with relapsed disease include [[arsenic trioxide]] and [[bone marrow transplant|allogeneic stem cell transplant]].
{{Hematological malignancy histology}}


==References== 
[[de:Promyelozytenleukämie]]
* Kumar, Vinay, Abul Abbas, and Nelson Fausto. ''Robbins and Cotran Pathologic Basis of Disease'', 7th ed. (2004). ISBN 81-8147-528-3
{{WikiDoc Help Menu}}
* Sacher, Ronald A. and Richard A. McPherson. ''Wildman's Clinical Interpretation of Laboratory Tests'', 11th ed. (2000). ISBN 0-8036-0270-7
{{WikiDoc Sources}}
* Dan Douer, et al. ''British Journal of Haematology'', vol. 122, pp. 563, Aug. 2003
* Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl J Med. 1998 Nov 5;339(19):1341-8.


==External Links==
[[Category:Disease]]
* http://www.trisenox.com/
* ACUTE MYELOID LEUKEMIA IN ADULTS [http://www.cancer.org/downloads/PUB/DOCS/SECTION36/124.pdf]
* The character Kate in "My Sister's Keeper" by Jodi Picoult has APL
 
{{Hematological malignancy histology}}
{{SIB}}
[[de:Promyelozytenleukämie]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Oncology]]
[[Category:Oncology]]
 
[[Category:Overview complete]]
{{WikiDoc Help Menu}}
[[Category:Up-To-Date]]
{{WikiDoc Sources}}
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 14:31, 29 October 2019

Template:DiseaseDisorder infobox

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia

CDC on Acute promyelocytic leukemia

Acute promyelocytic leukemia in the news

Blogs on Acute promyelocytic leukemia

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2] Grammar Reviewer: Natalie Harpenau, B.S.[3]

Synonyms and keywords: Acute progranulocytic leukemia; APL; AML with t(15;17)(q22;q12); PML-RARA and variants; FAB subtype M3; M3 variant

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Acute promyelocytic leukemia from Other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging studies | Other Diagnostic Studies

Treatment

Medical Therapy | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

de:Promyelozytenleukämie

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Acute_promyelocytic_leukemia&oldid=1586485"